Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

561
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
561
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

228
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
228
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

421
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
421
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

420
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
420
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

287
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
287

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vacuolization as a Novel Approach to Cancer Therapy.

Journal of biochemical and molecular toxicology·2026
Same author

3D printed drug delivery devices: recent promises and challenges.

Expert opinion on drug delivery·2026
Same author

Meloxicam Eluting 3D Printed 316L Stainless Steel Implants for Targeted Delivery in Bone Fixation Surgeries.

AAPS PharmSciTech·2026
Same author

Comparative Formulation and Physicochemical Evaluation of Orodispersible Films Fabricated via Pneumatic and Syringe-Based 3D Printing.

Pharmaceutical research·2025
Same author

Identification and Mechanistic Profiling of Indolin-2-One Derivatives That Induce ROS-Driven Intrinsic Apoptosis in Prostate and Colorectal Cancer Cells.

Journal of biochemical and molecular toxicology·2025
Same author

Intravenous clomiphene citrate pharmacokinetics in healthy mares as a first step toward use in reproduction.

American journal of veterinary research·2025

相关实验视频

Updated: May 6, 2026

3D Printing of Preclinical X-ray Computed Tomographic Data Sets
11:06

3D Printing of Preclinical X-ray Computed Tomographic Data Sets

Published on: March 22, 2013

40.5K

3D打印的剂量表,我们将走向何方?

Ishwor Poudel1, Nur Mita1,2, R Jayachandra Babu1

  • 1Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA.

Expert opinion on drug delivery
|July 12, 2024
PubMed
概括

3D打印 (3DP) 正在彻底改变药物产品开发,提供个性化的制药解决方案. 虽然监管指导方针仍在不断发展,3DP对医学的未来具有重大前景.

科学领域:

  • 制药科学 制药科学
  • 生物技术是生物技术.
  • 材料科学 材料科学 材料科学

背景情况:

  • 在过去的十年中,3D打印 (3DP) 已成为医疗保健和制造业的转型技术.
  • 制药行业对药物产品开发的3DP越来越感兴趣,美国FDA对3D打印平板电脑的批准凸显了这一点.

研究的目的:

  • 审查目前用于制药产品制造的3D打印技术.
  • 讨论新兴技术,包括人工智能 (AI),在制药3DP.
  • 为了解决3DP药物制造工业中的局限性和监管挑战.

主要方法:

  • 对用于制药产品制造的主要3D打印技术的审查.
  • 分析监管更新和现有的局限性.
  • 探索3DP在药品中的未来前景和潜力.

主要成果:

  • 3DP使得快速的原型设计和个性化药品发行成为可能.
  • 针对患者的药物配方存在显著的优势.
  • 该领域准备迎来指数级增长,由个性化趋势驱动.

结论:

  • 3D打印对于制药专业人士来说是一个改变范式的资产.
关键词:
通过3D打印打印3D打印.添加剂制造 添加剂制造 添加剂制造剂量形式 剂量形式药物输送是药物输送的过程.毒品产品 毒品产品 毒品产品

更多相关视频

Viability of Bioprinted Cellular Constructs Using a Three Dispenser Cartesian Printer
07:05

Viability of Bioprinted Cellular Constructs Using a Three Dispenser Cartesian Printer

Published on: September 22, 2015

10.0K
Agarose Fluid Gels Formed by Shear Processing During Gelation for Suspended 3D Bioprinting
07:26

Agarose Fluid Gels Formed by Shear Processing During Gelation for Suspended 3D Bioprinting

Published on: May 26, 2023

2.4K

相关实验视频

Last Updated: May 6, 2026

3D Printing of Preclinical X-ray Computed Tomographic Data Sets
11:06

3D Printing of Preclinical X-ray Computed Tomographic Data Sets

Published on: March 22, 2013

40.5K
Viability of Bioprinted Cellular Constructs Using a Three Dispenser Cartesian Printer
07:05

Viability of Bioprinted Cellular Constructs Using a Three Dispenser Cartesian Printer

Published on: September 22, 2015

10.0K
Agarose Fluid Gels Formed by Shear Processing During Gelation for Suspended 3D Bioprinting
07:26

Agarose Fluid Gels Formed by Shear Processing During Gelation for Suspended 3D Bioprinting

Published on: May 26, 2023

2.4K
  • 解决监管障碍对于大规模的工业采用至关重要.
  • 药品中3DP的未来指向增加个性化和创新.